Drug

Darovasertib clinical trials

Also written IDE196 and LXS196.

studies test it: 7
open now: 3
in phase 3: 3
first study started: 2016

How each study uses darovasertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the darovasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Darovasertib: 5

Development codes

IDE196: 4
LXS196: 2

Studies by the year they started

7 studies that test it; most in 2023 (2)

Studies that test darovasertib, by start year
Year	Studies
2016	1
2019	1
2022	1
2023	2
2026	2

By phase

A phase 1/2 study counts in both.

Phase 1: 2
Phase 2: 4
Phase 3: 3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Uveal Melanoma: 7

Who runs them

Industry 6 · Other 1

IDEAYA Biosciences (5) · St Vincent's Hospital, Sydney (1) · Novartis Pharmaceuticals (1)

Often tested with

Tested in the same studies.

Crizotinib (1) · Siremadlin (1)

Related medicines

As reviewed, each with the page that says it.

One of Protein Kinase Inhibitors source

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test darovasertib, phase 3 first.

Jan 2027IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaPhase 2/3 · IDEAYA Biosciences
Jan 2027Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPhase 1/2 · IDEAYA Biosciences
Apr 2027(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaPhase 2 · IDEAYA Biosciences

Studies

Open first, then newest update. How each study uses darovasertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Codes

What other systems call darovasertib · ClinicalTrials.gg INT016396

UNII (FDA) E0YF0M8O09DAROVASERTIBOne source FDA
NCI Thesaurus C124796DarovasertibOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	E0YF0M8O09	DAROVASERTIB	One source FDA
NCI Thesaurus	C124796	Darovasertib	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.